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INTRODUCTION
Until the past decade, respiratory infections in
immunocompromised patients were generally attributed
to cytomegalovirus (CMV) or other herpesviruses [1]. More
recently, epidemiologic studies have suggested that com-
munity-acquired respiratory virus (CRV) infections are
important causes of morbidity and mortality among
immunocompromised patients of all ages [1-5]. With the
advent of effective antiviral therapy and prophylaxis for
CMV infections, the relative prevalence of pneumonia
caused by CMV and that caused by the CRVs has shifted,
with CRV-associated pneumonias now more dominant [1].
The most common CRVs are the influenza viruses
(types A and B), respiratory syncytial virus (RSV), parain-
ﬂuenza viruses (1, 2, and 3), adenoviruses, and possibly rhi-
noviruses [3,4]. The clinical syndromes associated with these
viruses include the common cold, upper respiratory tract
disease, pharyngitis, laryngitis, tracheobronchitis, inﬂuenza-
like syndrome, bronchiolitis, and pneumonia. The causative
CRV cannot be identiﬁed by clinical diagnosis, as distinctive
presentations are not always associated with speciﬁc CRVs.
CRVs are generally transmitted by contact with secre-
tions from an infected person or a contaminated surface or
object. The virus is transferred to the nasal or oral mucosa
by hand. The influenza viruses, which are more virulent
than other CRVs, can also be spread by aerosol droplets.
CHARACTERISTICS OF CRV INFECTIONS IN IMMUNO-
COMPROMISED PATIENTS 
CRV infections in immunocompromised patients may
be differentiated from those in healthy persons by 3 major
characteristics: 
1. Prolonged infection. According to 8 published
reports summarized in a 1997 review [4], RSV, influenza
virus (types A and B), and parainﬂuenza virus type 3 infec-
tions persist longer in immunocompromised children than
in immunocompetent children. In immunocompromised
children, RSV shedding lasted >37 days in all studies, >50
days in 4 studies, and >100 days in 2 studies. In immuno-
competent children, RSV shedding lasted up to 21 days [4]. 
2. High frequency of nosocomial acquisition. Prolonged
hospital stays predispose immunocompromised patients to
nosocomial CRV infections. According to a 1997 review,
nosocomial acquisition rates for CRV infections in immuno-
compromised patients have ranged from 55% to 83% [4].
CRV infections may go undiagnosed in immunocompro-
mised adults because the signs and symptoms of upper respi-
ratory tract infection (URTI) may be minimal. Signs and
symptoms of lower respiratory tract infections (LRTIs)
caused by CRV may be difﬁcult to distinguish from those of
LRTIs caused by other opportunistic pathogens [6].
Immunocompromised adults with CRV infection tend to
have low viral loads with persistent viral shedding and to
remain infectious for prolonged periods. These infections
may be spread from 1 immunocompromised patient to
another either directly or indirectly via intermediary con-
tacts such as hospital personnel [4,7]. Hospital visitors—par-
ticularly young children, among whom the incidence of
CRV infections generally is high—are another source of
nosocomial CRV infection [4]. 
3. Greatly increased incidence of pneumonia and high
mortality. In healthy immunocompetent adults, CRV infec-
tion rarely leads to pneumonia or death, although reinfection
with RSV may cause moderately severe clinical symptoms,
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especially among the elderly [6]. However, published reports
from medical centers in the United States suggest that
approximately 50% to 75% of immunocompromised
patients with CRV who are receiving induction chemo-
therapy for leukemia or have undergone bone marrow
transplantation (BMT) develop pneumonia [1-4]. In these
reports, CRV mortality ranged from 9% to 45% [1,2,4].
PNEUMONIA IN IMMUNOCOMPROMISED PATIENTS WITH
CRV INFECTIONS
In a prospective surveillance study conducted at M.D.
Anderson Cancer Center (MDACC) in the 1990s, laboratory-
confirmed RSV, influenza, and parainfluenza respiratory
infections were associated with a high incidence of pneumo-
nia and high mortality among hospitalized BMT recipients
during the first 100 days after BMT and among patients
undergoing induction therapy for leukemia (Table 1) [4]. Of
the 156 infected patients, 100 (64%) developed pneumonia and
47 (30%) died. In posttransplantation BMT patients, the inci-
dence of pneumonia was greatest among patients infected with
inﬂuenza virus, but RSV infection was associated with greater
mortality [4].
Although mortality rates for BMT recipients with CRV
infections vary from center to center, the highest mortality
rates are generally associated with RSV and adenovirus
infections [3-5]. The incidence of adenovirus infection
among immunocompromised patients has varied widely
from study to study [5,8-11]. Mortality rates for adenovirus-
associated disease depend on the affected system, with those
for pneumonia and disseminated disease being the highest
[5,12].
CRV SEASONS
Among BMT recipients, the risk of respiratory virus
infection is influenced by the time since transplantation,
time relative to engraftment, absolute neutrophil count,
presence of graft-versus-host disease, patient age, relapse of
malignancy, and time of year. Adenoviruses are generally
present throughout the year. The rhinoviruses also occur
year round, but infection rates peak in spring and fall.
Parainﬂuenza viruses are most prevalent in the summer but
are present in spring and fall as well. RSV and inﬂuenza are
primarily winter viruses, with the RSV season preceding the
inﬂuenza season. 
In a 6-year surveillance study conducted simultaneously
among outpatients representing all socioeconomic groups in
Houston, Texas, and among immunocompromised inpa-
tients at MDACC from 1991 to 1997, we found that the
epidemiology of CRV infections among inpatients mirrored
that in the outpatient population [13]. This finding may
seem obvious, but it is important because it suggests a start-
ing point for identifying the pathogen causing respiratory
infection in an immunocompromised patient. If the patient
is wheezing and an RSV epidemic is ongoing in the commu-
nity, RSV should be suspected. 
Diagnosis of CRV Infections 
The prompt diagnosis of CRV infection in immunocom-
promised patients is clinically important for many reasons:
• Unnecessary testing is minimized
• Speciﬁc isolation precautions can be instituted
• Potential epidemic situations can be identiﬁed and appro-
priate action taken
• Speciﬁc antiviral therapy can be initiated
• Unnecessary empiric therapies can be discontinued 
Diagnostic Tests
Today, the state of the art in CRV diagnosis is rapid
detection of antigen or nucleic acid. Serologic testing is gen-
erally not clinically useful. Culture techniques remain useful
as backup methods and also as an approach to diagnosis of
complicated infections involving more than 1 pathogen.
However, replication in tissue culture is often too slow to be
an optimal diagnostic technique for CRVs in immunocom-
promised patients, in whom respiratory infections may
progress rapidly.
Several types of rapid detection tests are available today
for most CRVs (Table 2). Methods employed include anti-
gen detection by enzyme-linked immunosorbent assay
(ELISA), immunofluorescence (IF) assay, and polymerase
chain reaction (PCR) ampliﬁcation and enzymatic detection
by chemical reactions. A variety of tests are available to
detect RSV, inﬂuenza viruses, and parainﬂuenza viruses, but
diagnostic options for rhinoviruses and adenoviruses remain
limited. 
To obtain good results with rapid detection tests, a good
specimen is necessary. Upper respiratory tract specimens
obtained from nasal washes, nasopharyngeal aspirates, or
nasopharyngeal swabs are usually of higher quality than those
obtained by throat swabs (Table 2). Specimens obtained by
throat swab are generally adequate for detection of inﬂuenza
viruses and sometimes adequate for detection of parainﬂuenza
viruses, but they are not useful for RSV detection. 
The sensitivity of antigen detection tests depends on the
site from which the specimen is obtained, the type of speci-
men, and the viral load. In a comparative study of RSV diag-
nosis by culture or rapid antigen detection with ELISA, we
found that viral load in samples collected from both the
upper and lower respiratory tract of immunocompromised
adults was significantly lower than that of children: <5
plaque-forming units (PFU)/mL in nasal wash/throat swab
specimens obtained from more than half the adult patients
versus 1 to 2 million PFU/mL in specimens obtained from
pediatric patients [14]. Viral loads were generally higher in
specimens obtained from adult patients by bronchoalveolar
lavage (BAL). The sensitivity of rapid antigen testing with
Table 1. Documented Respiratory Virus Infections in Adult Leukemia or
BMT Patients at M.D. Anderson Cancer Center*
Number of Number with Number of
Infections Pneumonia (%) Deaths (%)
Respiratory syncytial virus
Leukemia 22 13 (59) 7 (32)
BMT 33 20 (61) 12 (36)
Influenza virus
Leukemia 27 21 (78) 9 (33)
BMT 20 14 (70) 5 (25)
Parainfluenza virus
Leukemia 9 6 (67) 4 (44)
BMT 45 26 (58) 10 (22)
*Reprinted from [4], with permission from Excerpta Medica Inc.
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ELISA for RSV in adult patients was only 15% with upper
respiratory tract samples but increased to 89% with BAL
specimens. In another study, 2 RSV rapid detection assays
(antigen detection by ELISA or by indirect IF) did not
detect documented RSV infections in nasal wash specimens
obtained from elderly nursing home patients. In this study,
specimens were cultured for RSV at the bedside [15]. RSV
was identiﬁed in only 1 of 11 specimens by the IF assay and
in none of the specimens by ELISA, compared with growth
in 5 of 11 viral cultures.
A reverse transcription PCR-enzyme hybridization assay
that detects and quantitates RNA from RSV, influenza
viruses A and B, and parainfluenza viruses 1, 2, and 3 has
been shown to be both highly sensitive and speciﬁc in nasal
wash and nasopharyngeal swab specimens obtained from
pediatric patients [16]. Many rapid detection inﬂuenza virus
assays are available. These assays are inexpensive, relatively
sensitive, and specific. Parainfluenza viruses may be diag-
nosed with IF rapid detection tests or with the reverse tran-
scription PCR-enzyme hybridization test described above. 
CONCLUSION
CRV infections are a signiﬁcant source of morbidity and
mortality among immunocompromised patients. In a sur-
veillance study at MDACC, infection with RSV, influenza
viruses, or parainﬂuenza viruses progressed to pneumonia in
>60% of adult BMT recipients and leukemia patients under-
going induction therapy [4]. Mortality rates generally range
up to 45% for patients with RSV infection and are some-
what lower for those infected with influenza viruses [3-5].
Rapid detection assays are available for these viruses,
although the sensitivity of some assays may be limited when
upper respiratory tract specimens from adult patients are
tested. Samples from the lower respiratory tract, such as
bronchoalveolar lavage, may help diagnose these infections
earlier. Early detection not only facilitates optimal manage-
ment of the infection but also can prevent wider transmis-
sion of these serious and potentially lethal infections.
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Table 2. Diagnostic Tests for Community Respiratory Viruses*
Virus Best Specimen Readily Cultured? Rapid Detection Tests
RSV NP aspirate Yes Antigen detection (ELISA)
Direct specimen, shell vial IF
PCR amplification
Influenza NP aspirate/swab Yes Antigen detection (ELISA)
Direct specimen, shell vial IF
Enzyme detection
Parainfluenza NP aspirate/swab Yes Direct specimen, shell vial IF
PCR amplification
Adenovirus Throat swab, blood, stool Yes IF
Rhinovirus NP aspirate No No
*NP indicates nasopharyngeal; IF, immunoﬂuorescence.
